Introduction
============

Cholangiocarcinoma is the most common malignancy of the bile duct epithelium ([@b1-ol-0-0-9043]). The global incidence of cholangiocarcinoma has increased from 0.32 to 0.85 per 100,000 individuals within last 30 years, an increase of 165% ([@b2-ol-0-0-9043]). Cholangiocarcinoma has become the second primary form of liver cancer after hepatocellular carcinoma, accounting for 10--15% of total primary liver cancer cases ([@b3-ol-0-0-9043]). However, the pathogenesis of the majority cholangiocarcinoma cases remains unclear; various high-risk factors have been associated with disease progression, including parasitic infection, primary sclerosing cholangitis, bile duct cysts, intrahepatic bile duct stones, toxins, inflammatory enteropathy, hepatitis B or C virus infection, liver cirrhosis, diabetes, obesity, alcohol consumption, tobacco and genetic polymorphisms ([@b4-ol-0-0-9043]). Cholangiocarcinoma is characterized by latency in its early stages, which contributes to the challenges of diagnosis, high levels of malignancy and rapid disease progression, leading to an unfavorable prognosis ([@b5-ol-0-0-9043]). Therefore, the identification of accurate novel molecular biomarkers is of substantial importance for early disease diagnosis, determination of the tumor differentiation stage and the prediction of prognosis.

CHD1L is an oncogene that was identified and cloned from the 1q21 chromosome region of human liver carcinoma cells in 1991. It has a full length of 2,980 bp, encoding an 89-kDa protein. CHD1L was observed to exert critical functions in the transcriptional regulation, chromosomal remodeling and protein-DNA interaction manipulation ([@b6-ol-0-0-9043]). Ahel *et al* ([@b7-ol-0-0-9043]) reported that CHD1L participated in DNA damage repair, interacting with the DNA damage site through an ATPase domain, dissociating from repaired DNA. The ATPase domain may loosen chromatin via interaction with poly ADP ribose to facilitate DNA repair. However, the overexpression of CHD1L could reduce the degree of chromatin loosening in tumor cells, which may result in the mismatch of DNA bases, potentially initiating tumorigenesis ([@b7-ol-0-0-9043]). A previous study determined that 58--78% of primary liver cancer cells expressed CHD1L ([@b8-ol-0-0-9043]). Tian *et al* ([@b9-ol-0-0-9043]) reported that CHD1L overexpression was associated with poorer patient prognosis. CHD1L was also detected in colorectal cancer tissue samples by Ji *et al* ([@b10-ol-0-0-9043]): The overexpression of CHD1L was associated with a large tumor size, deep tumor invasion and a high histological. Functional studies revealed that overexpression of CHD1L could promote the transfer of cells from G1- to S-phase and inhibit apoptosis, these results indicating that CHD1L serves notable roles in the pathogenesis of colorectal cancer. Su *et al* ([@b11-ol-0-0-9043]), evidenced by quantitative polymerase chain reaction (PCR) and western blot analyses, revealed that CHD1L was highly expressed in gastric cancer, and the overexpression of CHD1L was closely associated with remote metastasis and an unfavorable patient prognosis.

The DNA mismatch repair (MMR) system is activated once DNA damage is detected, so the integrity and stability of DNA can be maintained ([@b12-ol-0-0-9043]). The loss of function for DNA MMR could occur upon mutation of a DNA MMR system gene, leading to increased rates of DNA base pair mismatch and activator mutations in proto-oncogenes, or the inactivation of tumor suppressor genes, which eventually results in tumor progression ([@b12-ol-0-0-9043]). hMLH1 is one of the most important members of the DNA MMR system, identified by Bronner *et al* ([@b13-ol-0-0-9043]) during their investigation into hereditary non-polyposis colorectal cancer (HNPCC). hMLH1 is located at the 3p21.3--23 chromosomal region and encodes a 756 amino acid-long protein. The hMLH1 gene product was observed to interact with the mismatched gene together with repair enzymes, enhancing DNA repair ([@b13-ol-0-0-9043]). The downregulation of hMLH1 (including mutation, methylation and loss of heterozygosity) could lead to the loss of DNA MMR function and promote tumor progress ([@b13-ol-0-0-9043]). Zhang *et al* ([@b14-ol-0-0-9043]) reported that 90% of HNPCC cases were closely associated with mutations to hMLH1. The rate of hMLH1 loss was associated with the invasive depth of colon cancer, as evidenced by Gu *et al* ([@b15-ol-0-0-9043]) in their study on 195 patients with colon cancer. The latest research findings indicate that the methylation status of the hMLH1 gene may be of significance for evaluating the risk of recurrence in rectal cancer ([@b16-ol-0-0-9043]).

The objective of the present study was to investigate CHD1L and hMLH1 expression in patients with cholangiocarcinoma using immunohistological analysis; this was evaluated along with the signs of clinical manifestation and prognosis in order to evaluate their potential prognostic value.

Materials and methods
=====================

### Patients and clinicopathological parameters

The present study was approved by the Ethics Committee of The Second Affiliated Hospital of Nanchang University, (Nanchang, China). The formalin-fixed (Specimens were fixed in 10% formalin for 10 min at room temperature), 4-µm-thick paraffin-embedded cholangiocarcinoma tissues were obtained from 108 patients who were admitted to The Second Affiliated Hospital of Nanchang University (Nanchang, China) between the May 2005 and May 2014 \[including 84 male and 24 female patients, with a mean age of 58.26 (range, 40--76 years)\]. Normal bile duct tissues, collected 5 cm away from the tumor site, were obtained from 60 of the 108 patients. Written informed consent was provided by each participant. The inclusion criteria for patients included a diagnosis of cholangiocarcinoma prior to surgery, confirmed postoperatively, and no preoperative chemotherapy and radiotherapy administered. Patients with concurrent benign bile duct tumors or hepatocellular carcinoma were excluded from the study. Data regarding the clinicopathological parameters were also collected, including age, gender, gallstone history, hepatitis B virus surface antigen (HBsAg) presence, carbohydrate antigen 19-9 (CA19-9) serum level, tumor diameter and Tumor-Node-Metastasis (TNM) stage ([Table I](#tI-ol-0-0-9043){ref-type="table"}). TNM was assessed according to the definitions of the American Joint Committee on Cancer (AJCC), 7th edition ([@b17-ol-0-0-9043]).

### Immunohistochemical analysis

The expression of CHD1L and hMLH1 in cholangiocarcinoma and normal tissues was measured by using PV-9000 Two-Step Immunohistochemical Detection kit (Shanghai Ruiqi Technology Co., Ltd., Shanghai, China).

Rabbit anti-human MLH1 polyclonal antibodies (cat. no. 1167-1-AP; ProteinTech Group, Inc., Chicago, IL, USA; dilution, 1:100, 4°C overnight) and rabbit anti-human CHD1L polyclonal antibodies (cat. no. PAB22069; Abnova, Taipei, Taiwan; dilution, 1:100, 4°C overnight) were used as primary antibodies, combined with an immunohistochemical MaxVision^™^ kit (goat anti-rabbit IgG polymer; cat. no. KIT-5006; dilution, 1:500; Fuzhou Maixin Biotech Co. Ltd., Fuzhou, China), used according to the protocol of the manufacturer, for the detection of MLH1 and CHD1L. Primary antibodies were substituted with PBS for the negative controls and healthy tissues were used for the positive controls. The method of analysis was adapted from that of Plevová *et al* ([@b18-ol-0-0-9043]). The immunohistochemical staining was defined according to the stain intensity and number of positive cells from randomly selected five vision fields (×200 magnification) under an inverted fluorescence microscopy (CKX41; Olympus Corporation, Tokyo, Japan).

The number of positive cells were scored as follows: 0, no positive cells; 1, ≤25% of cells positive; 2, 26--50% positive cells; 3, 51--75% positive cells; 4, \>75% positive cells. The staining intensity was scored as follows: 0, colorless; 1, light yellow; 2, dark yellow; 4, brown. The final number was the sum of the scores for the proportion of positive cells and the staining intensity: 0--3, defined as (−); 4--5, defined as (+); 6--7 defined as (++); (+) and (++) were regarded as positive results.

### Statistical analysis

SPSS v.17.0 software (SPSS, Inc., Chicago, IL, USA) was used to perform statistical analysis in the current study. The data were analyzed using the χ^2^ test. The 3-year overall survival rate was assessed using the Kaplan-Meier method, and the inter-group comparisons were performed using the log-rank test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression of CHD1L in cholangiocarcinoma

The rate of CHD1L expression was 94.44% (34/36) in cholangiocarcinoma tissues, compared with only 40.00% (8/20) in non-cancerous tissues, a statistically significant difference (P\<0.05; [Table II](#tII-ol-0-0-9043){ref-type="table"}; [Fig. 1](#f1-ol-0-0-9043){ref-type="fig"}).

### Association between the expression of CHD1L or hMLH1 in cholangiocarcinoma and clinical manifestations

The expression of CHD1L was significantly associated with a history of gallstones, the serum CA19-9 level and TNM staging (P\<0.05). No significant association was determined to be present with gender, age, the presence of HBsAg or the tumor diameter (P\>0.05). hMLH1 expression levels in cholangiocarcinoma (28/36, 77.78%) were significantly lower than those in non-cancerous bile duct tissues (58/60, 96.67%), as determined via the aforementioned immunohistological analysis ([Table III](#tIII-ol-0-0-9043){ref-type="table"}; [Fig. 2](#f2-ol-0-0-9043){ref-type="fig"}). The expression of hMLH1 was significantly associated with gender (P\<0.001), age (P=0.006), serum CA19-9 level (P=0.006), the presence of HBsAg (P\<0.001), TNM staging and the tumor diameter (P\<0.05), but not with a history of gallstones (P\>0.05).

### Survival analysis for the CHD1L-positive and -negative groups, and the hMLH1-positive and -negative groups

A total of 50 patients were randomly selected from the 108 and were followed up for between 1 and 3 years. In total, 26/50 patients were lost during follow-up, and subsequently excluded from the analysis. Of the remaining 24 patients, 18 were CHD1L-positive and 6 were CHD1L-negative patients and 12 were hMLH1-positive and 12 were hMLH1-negative patients. Of these 9/24 patients (37.5%) survived to the end of the follow-up period, of whom 4 were CHD1L-positive and 5 were CHD1L-negative, 7 were hMLH1-positive and 2 were hMLH1-negative. The Kaplan-Meier survival curve indicated that the 3-year accumulative survival rate of CHD1L-positive patients was 17.90%, which was significantly lower than for CHD1L-negative patients (83.33%; P\<0.05; [Fig. 3](#f3-ol-0-0-9043){ref-type="fig"}). Furthermore, the 3-year overall survival rate of the hMLH1-positive patients was 38.90%, higher than for the hMLH1-negative patients (33.30%), although this was not a statistically significant difference (P\>0.05; [Fig. 4](#f4-ol-0-0-9043){ref-type="fig"}).

Discussion
==========

The genesis and development of cholangiocarcinoma are complicated processes with multiple steps and factors involved, including oncogene activation and the loss of tumor suppressor genes ([@b19-ol-0-0-9043]). Elucidation of the genes essential for cholangiocarcinoma initiation and progression would be of considerable value for disease diagnosis, prognosis and identifying disease progression ([@b1-ol-0-0-9043]). Recent studies have revealed that the expression levels of CHD1L are high in cases of glioma ([@b20-ol-0-0-9043]) and lung adenocarcinoma ([@b21-ol-0-0-9043]), and are associated with tumor diagnosis, advanced clinical stage and prognosis ([@b22-ol-0-0-9043]). In the current study, the high expression levels of CHD1L in cholangiocarcinoma and the low expression levels in non-cancerous tissues were detected with immunohistochemical analysis. Further analysis indicated that high expression of CHD1L was significantly associated with gallstone history, CA19-9 level and TNM stage (P\<0.05), and negatively associated with the overall patient survival rate.

According to a number of studies, hMLH1 was expressed in multiple types of malignancies at relatively low levels ([@b23-ol-0-0-9043]--[@b26-ol-0-0-9043]). Giedl *et al* ([@b23-ol-0-0-9043]) established that expression of hMLH1 was decreased in early onset bladder cancer, as confirmed by immunohistological analyses. Park *et al* ([@b24-ol-0-0-9043]) also obtained similar results using samples of sporadic rectal cancer tissues collected from 318 patients. In addition, decreased expression of hMLH1 was detected in primary non-small cell lung cancer cells using quantitative polymerase chain reaction ([@b25-ol-0-0-9043]). Through various immunohistochemical methods, Nam *et al* ([@b26-ol-0-0-9043]) determined that the low expression levels of hMLH1 in esophageal squamous cell carcinoma cells are associated with patient prognosis.

In the current study, the expression of hMLH1 in cholangiocarcinoma and non-cancerous tissues was assessed immunohistochemically. The expression of hMLH1 was significantly lower in cholangiocarcinoma tissues than in the adjacent normal tissues. Further analysis of expression patterns combined with clinicopathological characteristics including sex, age, gallstone history, HBsAg, CA19-9, TNM stage and tumor diameter, revealed that low expression levels of hMLH1 are significantly associated with age, gender, CA19-9 level, the presence of HBsAg, the TNM stage and tumor diameter. Kaplan-Meier survival curve analysis indicated that patients with lower expression levels of hMLH1 had shorter overall survival periods compared with patients with higher expression levels of hMLH1, although this was not a significant difference. However, the findings of the present study indicated that hMLH1 could be considered as a potential biomarker for prognosis of cholangiocarcinoma.

In conclusion, the results of the present study indicated that high expression levels of CHD1L and low expression levels of hMLH1 are present in cholangiocarcinoma tissues, and that their abnormal expression profile is closely associated with disease development and an unfavorable prognosis. However, the current study was retrospective, and further *in vivo* and *in vitro* studies are required in order to investigate the mechanisms by which CHD1L and hMLH1 are involved in the pathological process and affect the tumor invasion and clinical prognosis. Comprehensive research on CDH1L and hMLH1 could contribute to the development of novel advanced methods for the diagnosis and treatment of cholangiocarcinoma.
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###### 

Expression of CHD1L and hMLH1 and their association with clinicopathological characteristics.

                            CHD1L   hMLH1                     
  -------------------- ---- ------- ------- ------- ---- ---- ---------
  Sex                                                         
    Male               84   6       78      0.178   12   72   \<0.001
    Female             24   0       24              12   12   
  Age, years                                                  
    \<60               78   6       72      0.118   12   66   0.006
    ≥60                30   0       30              12   18   
  Gallstone history                                           
    Yes                48   6       42      0.005   6    42   0.300
    No                 60   0       60              18   42   
  HBsAg                                                       
    Negative           90   6       84      0.260   12   78   \<0.001
    Positive           18   0       18              12   6    
  CA19-9, U/ml                                                
    \<400              30   6       24      0.000   12   18   0.006
    ≥400               78   0       78              12   66   
  TNM stage                                                   
    Stage I            36   0       36      0.000   12   24   \<0.001
    Stage II           24   0       24              0    24   
    Stage III          24   6       18              12   12   
    Stage IV           24   0       24              0    24   
  Tumor diameter, cm                                          
    \<4                72   6       66      0.075   12   60   0.050
    ≥4                 36   0       36              12   24   

CHD1L, chromodomain helicase/ATPase DNA binding protein 1; hMLH1, human mutL homolog 1; CA19-9, carbohydrate antigen 19-9; TNM, Tumor-Node-Metastasis.

###### 

Comparison of chromodomain helicase/ATPase DNA binding protein 1 expression levels between cholangiocarcinoma patients and healthy controls.

  Group                Negative   Positive   Total   Positive rate, %   P-value
  -------------------- ---------- ---------- ------- ------------------ ---------
  Cholangiocarcinoma     6        102        108     94.44              \<0.001
  Normal tissue        36           24         60    40.00              

###### 

Comparison of human mutL homolog 1 expression levels between cholangiocarcinoma patients and healthy controls.

  Group                Negative   Positive   Total   Positive rate, %   P-value
  -------------------- ---------- ---------- ------- ------------------ ---------
  Cholangiocarcinoma   24         84         108     77.78              \<0.01
  Normal tissue          2        58           60    96.67              
